Covaxin booster may confer long-term protection against severe Covid-19, says Bharat Biotech© zeenews.india.com

Covaxin booster may confer long-term protection against severe Covid-19, says Bharat Biotech

, 8 news, a view

New Delhi: Hyderabad-based vaccine manufacturer Bharat Biotech said on Saturday(January 8) that its trials for Covaxin booster dose have shown 'long-term safety' with no serious adverse events.

Bharat Biotech said that 90 per cent of the recipients of the booster dose had a "detectable neutralising antibody response" against the wild-type strain, six months after the second Covid dose.

"The analysis showed that six months after a two-dose BBV152 vaccination series, cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined," the vaccine manufacturer said in a statement.